NDAINHALATIONGAS
Approved
Aug 2018
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
7
Data completeness
3/8 — Basic
NITROGEN, NF (nitrogen) by Universal Cells. Approved for critical illness, gastrointestinal neoplasms, postoperative complications and 7 more indications. First approved in 2018.
Drug data last refreshed 1w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NITROGEN, NF is an inhaled gas formulation approved in 2018 for multiple acute and chronic indications including critical illness, gastrointestinal neoplasms, postoperative complications, and bronchopulmonary dysplasia. The product operates as a therapeutic gas with no defined pharmacologic mechanism of action or class. Patient populations span from critically ill hospitalized patients to those with chronic conditions requiring nutritional or respiratory support.
Peak
Product is in peak revenue phase post-approval; teams are likely focused on market penetration and indication expansion rather than launch activities.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Worked on NITROGEN, NF at Universal Cells? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.